MedPath

Development of a Tailored Life-Sustaining Treatment Decision Support Intervention for Stroke Surrogate Decision Makers

Not Applicable
Completed
Conditions
Stroke
Interventions
Behavioral: Decision tool
Registration Number
NCT03427645
Lead Sponsor
University of Michigan
Brief Summary

The trial is testing an investigator-developed decision support tool for surrogate decision makers for stroke patients that are unable to make medical decisions for themselves.

A historical usual care control group will be enrolled during tool development. The tool will then be tested in surrogates of hospitalized stroke patients.

Detailed Description

Decision support tools, specifically recommended in the 2010 Affordable Care Act, have been shown to improve the quality of decisions and reduce burden on the decision maker in multiple clinical settings, yet almost none have focused on life-sustaining treatments in acute critical illness such as stroke. This study proposes a comprehensive frame shift in how the health care team and surrogates collaborate on decisions regarding life-sustaining treatments for acute illness, by developing a tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.

The two project phases are: 1) Decision support intervention development; and 2) Pilot testing in surrogates of hospitalized stroke patients. A novel ordinal prognostic model will be developed and incorporated into the tool.

The project expects 25 surrogate-patient pairs in the control group, and 25 surrogate-patient pairs in the intervention group, which equals a total of 100 subjects.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
106
Inclusion Criteria
  • Self-identify as the surrogate decision maker for eligible patient
  • Able to read and communicate in English without an interpreter
  • Limited to one surrogate per patient
Read More
Exclusion Criteria
  • No prior relationship with patient
  • Dementia or other cognitive or health condition that would impair their ability to participate

Patients:

Inclusion Criteria:

  • Ischemic stroke or spontaneous intracerebral hemorrhage

  • Impaired decisional capacity (per treating team)

  • Enrolled on or before full hospital day 5

  • Minimum illness severity (either):

    • National Institutes of Health Stroke Scale ≥ 10
    • Glasgow coma scale ≤12

Exclusion Criteria:

  • No surrogate available for study procedures
  • Already on comfort measures only
  • Physician refuses to allow approach for consent
  • Pregnancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Surrogate Decision Tool ArmDecision toolThis group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
Primary Outcome Measures
NameTimeMethod
Acceptability of the decision tool interventionImmediately post-intervention

The proportion of cases where the surrogate completes use of the tool with high acceptability using the Acceptability E-Scale. The Acceptability E-Scale is a 6-item scale. A score of 1 indicates a negative evaluation and 5 indicates a positive evaluation. A score of 3 indicates a neutral evaluation. An individual will be considered to have high acceptability if the average response across the 6 items is 4 or higher)

Secondary Outcome Measures
NameTimeMethod
Decisional Self Efficacy scaleWithin approximately 5 days of admission

11-item scale (a score of 0 indicates not at all confident and a 4 indicates very confident) with ordered categorical responses, converted to a 0-100 scale based on the average of the responses to each item. A score of 0 means extremely low self-efficacy and a score of 100 means extremely high self-efficacy

Accuracy of the surrogate's prognostic estimate for functional recoveryWithin approximately 5 days of admission

Calculated as the absolute value of the difference between the surrogate's estimate of the probability (0-100%) of return to functional independence by 90 days and the model based estimate of modified Rankin of 0-2. Range of this measure will be 0-100.

Trial Locations

Locations (1)

The University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath